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Diabetic subjects with clinical features of autonomic neuropathy may die suddenly 
and unexpectedlyl). In diabetes mellitus with autonomic neuropathy， QT interval 
prolongation in electrocardiogram has been reported by authors in a few groups2，3). 
The QT interval prolongation in electrocardiogram is associated with a lowered 
ventricular fibrillation threshold and with an occurrence of ventricular arrhythmias4). 
Thus， the QT interval prolongation has been expressive of predicting cardiovascular 
mortality in apparently healthy population5). Ewing et al. 6) have reported a 
significant association between the QT interval prolongation and the risk of dying 
unexpectedly in diabetes mellitus with autonomic neuropathy. Glibenclamide， one 
of sulfonylurea drugs widely used for the treatment of non-insulin dependent 
diabetes millitus (NIDDM)， iswell known to be a specific blocker of K+ ATP channels， 
and potentially has antiarrhythmic properties7，8). These suggest that glibenclamide 
influence the QT interval independently of diabetic neuropathy. In the present 
study， QT interval in NIDDM subjects treated with glibenclamide was compared 
with that in the su bjects treated with insulin or diet alone. 
Subjects and methods 
Subjects 
Sixty NIDDM patients (30 men and 30 women， aged 50-70 yrs) were enrolled in 
the present study， in whom the mode of therapy Cinsulin， glibenclamide， or diet 
alone) had not been changed for recent two years. Their diabetic condition was 
stable. They had not been treated with digitalis， (3-blockers or antiarrhythmic 
drugs that will influence QT interval. They had no hypertension and no abnormal 
findings in electrocardiogram (fresh or old myocardial infarction， right or left 
ventricular hypertrophy， arrhythmias or significant ST-T changes). Twenty (10 
men and 10 women) had been treated with insulin， twenty (10 men and 10 women) 
with glibenclamide (1.25-5.0 mg/day)， and twenty (10 men and 10 women) with 
diet alone. Clinical features of these patients were shown in Table 1. 
Measurements 01 QT interval 
All su bjects were registered a standard 12-1ead electrocardiogram two times in a 
different day， and the longest QT interval in leads 1， 1 or I was measured from 
the beginning of the first deflection of the QRS complex to the end of the T top， 
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where it merges with the electric baseline. Adjustment for heart rate was made 
according to Bazett' s form ula; QTc = QT / I頁R9l. The mean of the two QTc 
intervals was calculated. If the intervals measured fluctuated more than 10 msec， 
the standard electrocardiogram was taken one more time in another day to accept 
the mean interval calculated from the nearest interval out of three trials. In the 
same electrocardiogram， coefficient of variation of R-R interval (CV R-R) in resting 
was also calculated. 
Statistical anal yses 
The data were expressed as the mean + SD. Analyses of variance and two-tailed 
Student' s nonpaired t test were used for statistical evaluation. 
Results 
Clinical features 
The age and the duration of diabetes were not significantly different from each 
other among three groups， as shown in Table 1. The number of subjects with 
diabetic peripheral neuropathy and retinopathy was greater in NIDDM su bjects 
treated with insulin or glibenclamide than that in the subjects treated with diet 
alone; and that with nephropathy was greater in NIDDM subjects treated with 
insulin than that in the subjects treated with glibenclamide or diet alone. Glycosylated 
Table 1 Clinical features of NIDDM subjects 
treatment 
insulin diet gli benclamide 
(n =20) (n =20) (n =20) 
age(yr) 59.8土5.9 63. 6:t5. 4 62.6士5.3
duration of 16.9土7.6 13.2土7.3 13.5:t7.2 
diabetes (yr) 
periphera1 18/20 12/20 16/20 
neuropathy 
retinopathy 15/20 5/20 12/20 
nephropathy 7/20 3/20 4/20 
HbA1cC覧) 8.5:t2.0* 7.3:t1.0 7.7土0.8
CVR-R(覧) 1. 78:t0.80* 2 . 68 :t1. 22 2.22土0.80
QTc(msec) 407.9土15.5 399.8:t16.4 411.2:t15.0* 
The va1ues are means士 SD.
periphera1 neuropathy : 10s of deep tendon reflex. 
retinopathy : background or proliferative retinopathy. 
nephropathy : urine a1bumine above 300 mg/ day. 
* p < 0.05， significant1y di百Oerentfrom diet a1one. 
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hemoglobin concentration (HbA1c) in NIDDM subjects treated with insulin (8.5士2.0弘)
was significantly higher than that in the subjects treated with diet alone (7.3+1.0覧). 
CVR-R in NIDDM subjects treated with insulin (1. 78+0.80弘)was significantly lower 
than that in the subjects treated with diet alone (2.68+ 1. 22覧). 
QTc interval 
QTc interval in NIDDM subjects treated with glibenclamide (411.2+15.0 msec) 
was significantly longer than that in the subjects treated with diet alone (399.8+16.4 
msec). The number of subjects with moderate QTc prolongation (420くQTc話440
msec) was 8 in the insulin treated group， 2 in the diet， and 7 in the glibenclamide-
treated; and the number of subject with extensive QTc prolongation (>440 msec) 
was 1 only in the glibenclamide treated group (omitted in Table 1). 
Discussion 
The present study clearly demonstrated that QTc interval in NIDDM subjects 
treated with glibenclamide was significantly longer than that in the subjects treated 
with diet alone. Slightly prolonged QTc interval in NIDDM su bjects treated with 
insulin may be due to the diabetic autonomic neuropathy， because CV R-R， which is 
known to decrease coincidentally with the severity of diabetic autonomic neuropathy， 
was significantly lower in NIDDM subjects treated with insulin than that in NIDDM 
su bjects treated with diet alone. However， CV R-R in NIDDM su bjects treated with 
glibenclamide was not significantly different from that in the subjects treated with 
diet alone， suggesting that the significant prolongation of the QTc interval in 
NIDDM subjects treated with glibenclamide was not resulted from diabetic autonomic 
neuropathy. 
The results of previous studies7，8) that glibenclamide has an antiarrhythmic effect 
are contradictory to our present results that glibenclamide caused the prolongation 
of the QTc interval that may be associated with an occurrence of ventricular 
arrhythmias6) . Although the QTc interval is well known to be influenced by 
electrolyte abnormalities， the present subjects did not have any electrolyte abnormalities 
in routine laboratory examinations. 
As the present study was the cross-sectional study， the changes of QTc interval 
before and after the treatment with glibenclamide in the same patient remain to be 
elucidated. In the previous UGDP studylO)， tolbutamide， one of sulfonylurea 
drugs， has been reported to increase the incidence of ischemic heart disease in adult 
diabetic subjects， suggesting that sulfonylurea drugs have a cardiotoxic effect. 
Although the mechanism by which glibenclamide lengthens the QTc interval 
remains to be elucidated， careful 0 bservation should be necessary to evaluate 
whether or not the QT prolongation in NIDDM patients treated with glibenclamide 
has a clinical significance. 
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Summary 
To evaluate the possible role of glibenclamide， one of hypoglycemic sulfonylurea 
agents and a specific blocker of K九TP channels， in QTc interval in diabetes 
mellitus， QTc interval in a standard 12-1ead electrocardiogram was compared in 60 
NIDDM patients treated either with insulin， glibenclamide or diet alone. The QTc 
interval in the group treated with glibenclamide was 411.2士 15.0msec (means+SD)， 
and was significantly longer (pく0.05)than that， 399.8士 16.4msec， in the group 
treated with diet alone. CV R-R in the group treated with gli benclamide， however， 
was not significantly different from that in the group treated with diet alone. 
These results indicate that glibenclamide lengthens the QTc interval in NIDDM 
subjects independently of autonomic neuropathy. 
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